Analysis of hyperglycaemia adverse drug reactions of PCSK9 inhibi-tors and statins based on FAERS database
10.12092/j.issn.1009-2501.2024.07.005
- VernacularTitle:基于FAERS数据库的PCSK9抑制剂和他汀类药物的高血糖不良反应分析
- Author:
Anqi LOU
1
;
Quanzhi LI
;
Shuang HAN
;
Siyuan ZHU
;
Wei ZHANG
Author Information
1. 首都医科大学附属北京积水潭医院药学部,北京 100035
- Keywords:
PCSK9 inhibitors;
adverse events re-porting system;
hyperglycaemia;
signal mining
- From:
Chinese Journal of Clinical Pharmacology and Therapeutics
2024;29(7):762-767
- CountryChina
- Language:Chinese
-
Abstract:
AIM:To compare the risk of hypergly-caemia with PCSK9 inhibitors versus statins,based on U.S.Food and Drug Administration Adverse Events Reporting System(FAERS).METHODS:The hyperglycaemia reports induced by"alirocumab","evolocumab","atorvastatin"and"rosuvastatin"were utilized as the first suspected drugs from the database of FAERS from 2016 to the third quarter of 2023.The report odd ratio(ROR)method was employed.RESULTS:Based on the FAERS database,the ROR(95％CI)for hyperglycaemia due to Ali-rocumab versus Atorvastatin and Rosuvastatin were 0.628(0.545,0.724)and 0.307(0.263,0.357),the ROR(95％CI)for hyperglycaemia due to Evoloc-umab were 0.817(0.750,0.889)and 0.399(0.361,0.441),all generated no adverse reaction signals.The ROR(95％CI)for hyperglycaemia due to Ali-rocumab and Evolocumab versus all other drugs in FAERS were 1.488(1.315,1.682)and 1.934(1.845,2.027),all generated adverse reaction signals,re-spectively.CONCLUSION:Based on the FAERS data-base,PCSK9 inhibitors have a lower risk of hyper-glycemia than statins and deserve clinical attention.
